Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it ...

A new policy from the NIH in the US will cut billions of dollars of funding for research organisations and hospitals outside ...

The application has been submitted by the capital investment arm of insurance company Aviva and mixed-use developer Socius, ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

Informed consent is a foundational element of every clinical trial. Yet, the traditional paper-based process has long been ...

According to the WSJ, the universal vaccine project is being pioneered by two recently appointed senior scientists in the NIH ...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, ...

According to NICE's Early Value Assessment (EVA) guidance on the technology, automated use of DERM "could result in more ...

How does market access impact the pharmaceutical commercialisation journey, and what role does it play in driving success ...

Despite these benefits, biosimilar medicines remain under-recognised and underused in many markets. Real-world uptake often ...

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the ...

But international agreements are notoriously difficult to enforce, and pharma companies and patient advocates who were ...